WO1995003042A1 - Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues - Google Patents

Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues Download PDF

Info

Publication number
WO1995003042A1
WO1995003042A1 PCT/US1994/008276 US9408276W WO9503042A1 WO 1995003042 A1 WO1995003042 A1 WO 1995003042A1 US 9408276 W US9408276 W US 9408276W WO 9503042 A1 WO9503042 A1 WO 9503042A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
replication
formula
inhibiting
pharmaceutically acceptable
Prior art date
Application number
PCT/US1994/008276
Other languages
English (en)
Inventor
Alison Mary Badger
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP94922685A priority Critical patent/EP0711160A4/fr
Priority to NZ269991A priority patent/NZ269991A/xx
Priority to JP7505332A priority patent/JPH09500648A/ja
Priority to AU73709/94A priority patent/AU7370994A/en
Publication of WO1995003042A1 publication Critical patent/WO1995003042A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • This invention relates to a method of inhibiting the replication of human immunodeficiency viruses (HIV) in HIV seropositive humans which comprises administering to such human an effective amount of a substituted azaspirane.
  • HIV human immunodeficiency viruses
  • CD8+ T cells have been shown to inhibit the replication of HIV in cultures of CD4+ cells from asymptomatic HIV seropositive individuals (Brinchmann et al. CD8+ T cells L Immunol. 1442961-2966 (1990)).
  • the immunosuppressive compound cyclosporin A (CsA) has demonstrated a protective effect in several animal models of viral infection. Particularly, chronic treatment with CsA before and after infection with LP-BM5 murine leukemia virus has proven effective against the development of immunodeficiency disease (Cerny, A. et al. Eur. J. Immunol. 21:1747-50 (1991)).
  • Badger I discloses compounds of Formula I as a class of novel compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
  • Rl and R-2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R and R- when taken together is 5-10; or R* and R- together form a cyclic alkyl group having 3-7 carbon atoms;
  • R3 and R ⁇ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R ⁇ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R- ⁇ are propyl, R3 and R 4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R-2 are propyl, R3 and R 4 are ethyl, m is 1 and n is 3 which is N,N-diethyl-8,8-dipropyl-2- azaspiro[4.5]decane-2-propanamine dihydrochloride.
  • a particularly preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R2 are propyl, R3 and R 4 are joined together with the nitrogen to form a piperidine ring, m is 1 and n is 3 which is 8,8-dipropyl-2-azaspiro[4.5]decane-2-piperidinopropyl dihydrochloride.
  • This invention discloses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for inhibiting HIV replication in HIV seropositive humans.
  • the compounds of Formula I are tested for their ability to inhibit HIV replication in the assay described in Sperber, et al., AIDS Research and Human Retroviruses. 9 No.l.91-98.
  • This invention relates to a method of inhibiting HIV replication which comprises administering to an HIV seropositive human an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof.
  • a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such human in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No. 4,963,557.
  • a compound of Formula (I) ("Active Ingredient") or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to an HIV seropositive human in an amount sufficient to inhibit HIV replication.
  • the route of administration of the Formula (I) compound is not critical but is usually oral or parenteral, preferably oral.
  • parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • the daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 1 mg/kg.
  • each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • the compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils
  • the daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg kg of total body weight.
  • each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
  • an active ingredient While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques.
  • the method of this invention of inhibiting HIV replication in HIV seropositive humans comprises administering to a subject in need of such inhibition an effective HIV replication inhibiting amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in inhibiting HIV replication in HIV seropositive humans.
  • the invention also provides for a pharmaceutical composition for use inhibiting HIV replication in HIV seropositive humans which comprises a compound of Formula I and a pharmaceutically acceptable carrier.
  • the invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula I which comprises bringing the compound of Formula I into association with the pharmaceutically acceptable carrier or diluent.
  • the compounds of the present invention can be co-administered with further active ingredients, such as compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT)).
  • further active ingredients such as compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT)).
  • EXAMPLE 1 - CAPSULE COMPOSITION An oral dosage form for administering Formula (I) compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.
  • An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
  • Example 3 Tablet Composition
  • sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table II below are mixed and granulated in the proportions shown with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procédé d'inhibition de la réplication des virus de l'immunodéficience humaine (VIH) chez des sujets humains séropositifs VIH, qui consiste à administrer à ces sujets une quantité efficace d'un azaspiranne substitué.
PCT/US1994/008276 1993-07-23 1994-07-22 Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues WO1995003042A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP94922685A EP0711160A4 (fr) 1993-07-23 1994-07-22 Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues
NZ269991A NZ269991A (en) 1993-07-23 1994-07-22 Inhibiting hiv replication; comprises use of azaspirane compounds to prepare medicaments
JP7505332A JPH09500648A (ja) 1993-07-23 1994-07-22 置換アザスピランによるヒト免疫不全ウイルス複製の阻害法
AU73709/94A AU7370994A (en) 1993-07-23 1994-07-22 Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9315340.1 1993-07-23
GB939315340A GB9315340D0 (en) 1993-07-23 1993-07-23 Methods

Publications (1)

Publication Number Publication Date
WO1995003042A1 true WO1995003042A1 (fr) 1995-02-02

Family

ID=10739357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008276 WO1995003042A1 (fr) 1993-07-23 1994-07-22 Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues

Country Status (9)

Country Link
EP (1) EP0711160A4 (fr)
JP (1) JPH09500648A (fr)
CN (1) CN1130871A (fr)
AU (1) AU7370994A (fr)
CA (1) CA2167842A1 (fr)
GB (1) GB9315340D0 (fr)
NZ (1) NZ269991A (fr)
WO (1) WO1995003042A1 (fr)
ZA (1) ZA945418B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713391A1 (fr) * 1993-07-23 1996-05-29 Smithkline Beecham Corporation Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues
EP0717622A1 (fr) * 1993-07-23 1996-06-26 Smithkline Beecham Corporation Procedes de traitement du vih au moyen d'azaspiranes
US5744495A (en) * 1995-07-13 1998-04-28 Smithkline Beecham Corporation N, N-diethyl-8, 8-dipropyl-2-azaspiro 4.5! decane-2-propanamine
US6025364A (en) * 1996-05-17 2000-02-15 Anormed, Inc. Method of treating asthma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
GB9201804D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9201803D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9315298D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315306D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 117, No. 23. issued 07 December 1992, BADGER et al.: "Azaspirane Derivatives as Cytokine Inhibitors", see page 83, column 2, abstract no. 226312z; & WO,A,9214462. *
CHEMICAL ABSTRACTS, Volume 119, No. 17, issued 25 October 1993, BADGER: "Preventing or Delaying Occurrence of Acquired Immunodeficiency Syndrome with Azaspiranes", see page 90, column 1, abstract no. 174173z; & WO,A,9314760. *
See also references of EP0711160A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713391A1 (fr) * 1993-07-23 1996-05-29 Smithkline Beecham Corporation Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues
EP0717622A1 (fr) * 1993-07-23 1996-06-26 Smithkline Beecham Corporation Procedes de traitement du vih au moyen d'azaspiranes
EP0713391A4 (fr) * 1993-07-23 1998-09-09 Smithkline Beecham Corp Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues
EP0717622A4 (fr) * 1993-07-23 1998-09-09 Smithkline Beecham Corp Procedes de traitement du vih au moyen d'azaspiranes
US5744495A (en) * 1995-07-13 1998-04-28 Smithkline Beecham Corporation N, N-diethyl-8, 8-dipropyl-2-azaspiro 4.5! decane-2-propanamine
US6025364A (en) * 1996-05-17 2000-02-15 Anormed, Inc. Method of treating asthma

Also Published As

Publication number Publication date
EP0711160A4 (fr) 1998-09-09
AU7370994A (en) 1995-02-20
JPH09500648A (ja) 1997-01-21
EP0711160A1 (fr) 1996-05-15
CN1130871A (zh) 1996-09-11
ZA945418B (en) 1995-05-10
CA2167842A1 (fr) 1995-02-02
GB9315340D0 (en) 1993-09-08
NZ269991A (en) 1999-07-29

Similar Documents

Publication Publication Date Title
DK164441B (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
UA81003C2 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450
EP0713391A1 (fr) Procede d'inhibition de la production de virus de l'immunodeficience chez l'homme au moyen d'azaspiranes substitues
WO1995003042A1 (fr) Procede d'inhibition de la replication des virus de l'immunodeficience humaine a l'aide d'azaspirannes substitues
US5482959A (en) Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds
EP0717622A1 (fr) Procedes de traitement du vih au moyen d'azaspiranes
AU3595193A (en) A method for delaying HIV induced AIDS by administration of substituted azasperane compounds
CA2066834A1 (fr) Utilisation de ligands du recepteur glycine/nmda pour le traitement de la pharmacodependance et du sevrage
AU710542B2 (en) Use of substituted azaspirane in the treatment of asthma
US5786376A (en) Methods of treating opportunistic infections with azaspiranes
AU684384B2 (en) Method of treating opportunistic infections with azaspiranes
WO2020237096A1 (fr) Combinaison pour baisser le phosphate sérique chez un patient
JPH09500647A (ja) 置換アザスピランによるヒト免疫不全ウイルス産生の阻害法
EP0996445A1 (fr) Traitement et prevention de maladies cardiaques au moyen d'inhibiteurs specifiques du recaptage de la serotonine (ssri)
WO1995003048A1 (fr) Azaspiranes anti-hiv
MXPA98009596A (en) Use of azaspiran substituted in the treatment of a
WO1995003046A1 (fr) Procede d'inhibition de la production de vih
WO1995003047A1 (fr) Traitements s'exercant contre le virus de l'immunodeficience chez l'homme

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193381.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SI SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2167842

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1996 586846

Country of ref document: US

Date of ref document: 19960123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 269991

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994922685

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994922685

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994922685

Country of ref document: EP